President Trump Says If We Don't Make Steel Ourselves, We Can't Defend Ourselves
https://www.youtube.com/watch?v=TmNee1tFImc
Stocks · News reference
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday
U.S. stocks were down as Dow Jones fell 450 points on Thursday. Lockheed Martin (LMT) shares rose 11.4% on better-than-expected results. Other big gainers were NVE Corp (NVEC), Gibo Holdings Ltd (GIBO), Novocure Ltd (NVCR), Cleveland-Cliffs Inc (CLF), Merlin Inc (MRLN), Medpace Holdings Inc (MEDP), Oatly Group AB (OTLY), Imax Corp (IMAX), United Rentals Inc (URI), Oceaneering International Inc (OII), and Quest Diagnostics Inc (DGX).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Microsoft To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for INSP, SECZ, CLF and WAT, while cutting targets for CRDO, CL and TTMI; ratings remained unchanged.
GLJ Research Maintains Buy on Cleveland-Cliffs, Raises Price Target to $17.48
GLJ Research analyst Gordon L. Johnson maintains Cleveland-Cliffs (NYSE:CLF) with a Buy and raises the price target from $15.6 to $17.48.
GLJ Research Reiterates Buy on Cleveland-Cliffs, Maintains $15.6 Price Target
GLJ Research analyst Gordon L. Johnson reiterates Cleveland-Cliffs (NYSE:CLF) with a Buy and maintains $15.6 price target.
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments
The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.
Is This the Right Time to Add DGX Stock to Your Portfolio?
Quest Diagnostics (DGX) is experiencing growth across physician, hospital, and consumer channels, driven by customer wins and an expanding advanced diagnostics portfolio delivering double-digit growth. The company targets 3% annual cost savings through AI and automation initiatives. However, reimbursement uncertainty, cost pressures, and elevated debt of $5.63 billion remain concerns that could impact margins and financial flexibility.